Fresh Tracks Therapeutics (NASDAQ:FRTX) Shares Down 1.1%

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTXGet Free Report) shares dropped 1.1% during mid-day trading on Wednesday . The stock traded as low as $0.88 and last traded at $0.90. Approximately 76,272 shares traded hands during trading, a decline of 87% from the average daily volume of 590,789 shares. The stock had previously closed at $0.91.

Fresh Tracks Therapeutics Stock Performance

The business’s fifty day moving average price is $0.89 and its 200-day moving average price is $0.73. The stock has a market cap of $4.78 million, a PE ratio of -0.29 and a beta of 0.33.

Fresh Tracks Therapeutics (NASDAQ:FRTXGet Free Report) last issued its quarterly earnings data on Monday, November 13th. The company reported $0.32 earnings per share for the quarter. The firm had revenue of $7.94 million for the quarter. Fresh Tracks Therapeutics had a negative net margin of 91.29% and a negative return on equity of 102.00%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Fresh Tracks Therapeutics stock. GTS Securities LLC purchased a new position in Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTXFree Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,100 shares of the company’s stock, valued at approximately $49,000. GTS Securities LLC owned 0.84% of Fresh Tracks Therapeutics at the end of the most recent reporting period. 1.68% of the stock is currently owned by institutional investors.

Fresh Tracks Therapeutics Company Profile

(Get Free Report)

Fresh Tracks Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors.

Featured Stories

Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with's FREE daily email newsletter.